Chlorogenic and caftaric acids in liver toxicity and oxidative stress induced by methamphetamine

Journal of Toxicology

Volumn 2014, Issue , 2014, Pages

  Koriem, Khaled M M ^a,b   Soliman, Rowan E ^c  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b ADVANCED MEDICAL AND DENTAL INSTITUTE   (Malaysia)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAFTARIC ACID; CHLOROGENIC ACID; CHOLESTEROL; DOPAMINE; GLOBULIN; GLUTATHIONE PEROXIDASE; LIVER PROTECTIVE AGENT; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; METHAMPHETAMINE; NITRIC OXIDE; NORADRENALIN; POLYPHENOL; SEROTONIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALBINO MOUSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTOXICATION; ENZYME BLOOD LEVEL; HISTOCHEMISTRY; HISTOPATHOLOGY; LIVER FUNCTION; LIVER PROTECTION; LIVER TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; TISSUE PREPARATION;

RATTUS;

EID: 84924076876     PISSN: 16878191     EISSN: 16878205     Source Type: Journal    
DOI: 10.1155/2014/583494     Document Type: Article

References (73)

1. Office of Applied Studies, "Primary methamphetamine/amphetamine treatment admissions: 1992-2002," The DASIS Report, Substance Abuse & Mental Health Services Administration, 2004.
2. NSDUH Report, Methamphetamine Use, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, Md, USA, 2007.
3. Office of Applied Studies, "Emergency Department Trends from Drug Abuse Warning Network, Final Estimates 1995-2002," DHHS Publication SMA 03-3780, DAWN Series D-24, Substance Abuse and Mental Health Services Administration, Rockville, Md, USA, 2003.
4. R. Gonzales, L. Mooney, and R. A. Rawson, "The methamphetamine problem in the United States," Annual Review of Public Health, vol. 31, pp. 385-398, 2010.
5. J. R. Richards, E. B. Johnson, R. W. Stark, and R. W. Derlet, "Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study," The American Journal of Emergency Medicine, vol. 17, no. 7, pp. 681-685, 1999.
6. N. Shima, I. Miyawaki, K. Bando et al., "Influences of methamphetamine-induced acute intoxication on urinary and plasma metabolic profiles in the rat," Toxicology, vol. 287, no. 1-3, pp. 29-37, 2011.
7. A. L. Jones and K. J. Simpson, "Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications," Alimentary Pharmacology and Therapeutics, vol. 13, no. 2, pp. 129-133, 1999.
8. F. Carvalho, F. Remião, M. E. Soares, R. Catarino, G. Queiroz, and M. L. Bastos, "d-Amphetamine-induced hepatotoxicity: Possibie contribution of catecholamines and hyperthermia to the effect studied in isolated rat hepatocytes," Archives of Toxicology, vol. 71, no. 7, pp. 429-436, 1997.
9. Y. Kamijo, K. Soma, M. Nishida, A. Namera, and T. Ohwada, "Acute liver failure following intravenous methamphetamine," Veterinary and Human Toxicology, vol. 44, no. 4, pp. 216-217, 2002.
10. L. J. Mooney, S. Glasner-Edwards, R. A. Rawson, and W. Ling, "Medical effects of methamphetamine use," in Methamphetamine Addiction: From Basic Science to Treatment, J. M. Roll, R. A. Rawson, W. Ling, and S. Shoptaw, Eds., pp. 117-142, The Guilford Press, New York, NY, USA, 2009.
11. Q. Yu, D. F. Larson, and R. R. Watson, "Heart disease, methamphetamine and AIDS," Life Sciences, vol. 73, no. 2, pp. 129-140, 2003.
12. T. E. Albertson, R.W. Derlet, and B. E. van Hoozen, "Methamphetamine and the expanding complications of amphetamines," Western Journal of Medicine, vol. 170, no. 4, pp. 214-219, 1999.
13. S. Darke, S. Kaye, R. McKetin, and J. Duflou, "Major physical and psychological harms of methamphetamine use," Drug and Alcohol Review, vol. 27, no. 3, pp. 253-262, 2008.
14. B. D. Homer, T. M. Solomon, R. W. Moeller, A. Mascia, L. DeRaleau, and P. N. Halkitis, "Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications," Psychological Bulletin, vol. 134, no. 2, pp. 301-310, 2008.
15. J. C. Scott, S. P. Woods, G. E. Matt et al., "Neurocognitive effects of methamphetamine: a critical review and meta-analysis," Neuropsychology Review, vol. 17, no. 3, pp. 275-297, 2007.
16. J. E. Zweben, J. B. Cohen, D. Christian et al., "Psychiatric symptoms in methamphetamine users," The American Journal on Addictions, vol. 13, no. 2, pp. 181-190, 2004.
17. S. Glasner-Edwards, P. Marinelli-Casey, M. Hillhouse, A. Ang, L. J. Mooney, and R. Rawson, "Depression among methamphetamine users: association with outcomes from the methamphetamine treatment project at 3-year follow-up," Journal of Nervous and Mental Disease, vol. 197, no. 4, pp. 225-231, 2009.
18. C.W. Meredith, C. Jaffe, K. Ang-Lee, and A. J. Saxon, "Implications of chronic methamphetamine use: a literature review," Harvard Review of Psychiatry, vol. 13, no. 3, pp. 141-154, 2005.
19. R. C. Callaghan, J. K. Cunningham, P. Allebeck et al., "Methamphetamine use and schizophrenia: a population-based cohort study in California,"The American Journal of Psychiatry, vol. 169, no. 4, pp. 389-396, 2012.
20. R. C. Callaghan, J. K. Cunningham, J. Sykes, and S. J. Kish, "Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs," Drug and Alcohol Dependence, vol. 120, no. 1-3, pp. 35-40, 2012.
21. I. Tokunaga, S. Kubo, A. Ishigami, T. Gotohda, and O. Kitamura, "Changes in renal function and oxidative damage in methamphetamine-treated rat," Legal Medicine, vol. 8, no. 1, pp. 16-21, 2006.
22. P. Duh, Y. Tu, and G. Yen, "Antioxidant activity of water extract of haring jury (Chrysanthemummorifolium Ramat)," LWT-Food Science and Technology, vol. 32, no. 5, pp. 269-277, 1999.
23. M. E. Büyükokuroʇlu, I. Gülçin, M. Oktay, and O. I. Küfrevioʇlu, "In vitro antioxidant properties of dantrolene sodium," Pharmacological Research, vol. 44, pp. 491-495, 2001.
24. M. T. Shrem and P. N. Halkitis, "Methamphetamine abuse in the United States: contextual, psychological and sociological considerations," Journal of Health Psychology, vol. 13, no. 5, pp. 669-679, 2008.
25. D. J. Newman, G. M. Cragg, and K. M. Snader, "Natural products as sources of new drugs over the period 1981-2002," Journal of Natural Products, vol. 66, no. 7, pp. 1022-1037, 2003.
26. M. P. Gonthier, C. Remesy, A. Scalbert et al., "Microbial metabolism of caffeic acid and its esters chlorogenic and caftaric acids by human faecal microbiota in vitro," Biomedicine and Pharmacotherapy, vol. 60, no. 9, pp. 536-540, 2006.
27. A. S. Meyer, J. L. Donovan, D. A. Pearson, A. L. Waterhouse, and E. N. Frankel, "Fruit hydroxycinnamic acids inhibit low density lipoprotein oxidation in vitro," Journal of Agricultural and Food Chemistry, vol. 46, no. 5, pp. 1783-1787, 1998.
28. L. R. Fukumoto and G. Mazza, "Assessing antioxidant and prooxidant activities of phenolic compounds," Journal of Agricultural and Food Chemistry, vol. 48, no. 8, pp. 3597-3604, 2000.
29. N. Kerry and C. Rice-Evans, "Peroxynitrite oxidises catechols to o-quinones," FEBS Letters, vol. 437, no. 3, pp. 167-171, 1998.
30. D. Bassil, D. P. Makris, and P. Kefalas, "Oxidation of caffeic acid in the presence of L-cysteine: isolation of 2-S-cysteinylcaffeic acid and evaluation of its antioxidant properties," Food Research International, vol. 38, no. 4, pp. 395-402, 2005.
31. Y. Zhao, J. Wang, O. Ballevre, H. Luo, and W. Zhang, "Antihypertensive effects and mechanisms of chlorogenic acids," Hypertension Research, vol. 35, no. 4, pp. 370-374, 2012.
32. W. Shen, R. Qi, J. Zhang et al., "Chlorogenic acid inhibits LPS-induced microglial activation and improves survival of dopaminergic neurons," Brain Research Bulletin, vol. 88, no. 5, pp. 487-494, 2012.
33. G. M. Raso, M. Pacilio, G. di Carlo, E. Esposito, L. Pinto, and R. Meli, "In-vivo and in-vitro anti-inflammatory effect of Echinacea purpurea and Hypericum perforatum," Journal of Pharmacy and Pharmacology, vol. 54, no. 10, pp. 1379-1383, 2002.
34. B. Barrett, "Medicinal properties of Echinacea: a critical review," Phytomedicine, vol. 10, no. 1, pp. 66-86, 2003.
35. R. Gao, Y. Lin, G. Liang, B. Yu, and Y. Gao, "Comparative pharmacokinetic study of chlorogenic acid after oral administration of lonicerae japonicae flos and shuang-huang-lian in normal and febrile rats," Phytotherapy Research, vol. 28, no. 1, pp. 144-147, 2014.
36. S. Arimoto-Kobayashi, X. Zhang, Y. Yuhara, T. Kamiya, T. Negishi, and G. Okamoto, "Chemopreventive effects of the juice of Vitis coignetiae Pulliat on two-stagemouse skin carcinogenesis," Nutrition and Cancer, vol. 65, no. 3, pp. 440-450, 2013.
37. S. Reitman and S. Frankel, "Acolorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases,"The American Journal of Clinical Pathology, vol. 28, no. 1, pp. 56-63, 1957.
38. M. I. Walters and H. W. Gerarde, "An ultramicromethod for the determination of conjugated and total bilirubin in serumor plasma," Microchemical Journal, vol. 15, no. 2, pp. 231-243, 1970.
39. P. R. Kind and E. J. King, "Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine," Journal of Clinical Pathology, vol. 7, no. 4, pp. 322-326, 1954.
40. A. G. Gornall, C. J. Bardawill, and M. M. David, "Determination of serum proteins by means of the biuret reaction.," The Journal of biological chemistry, vol. 177, no. 2, pp. 751-766, 1949.
41. F. Drupt, "Determination of serum albumin by bromocresol green," Pharmaceutical Biology, vol. 8, pp. 77-99, 1974.
42. A. L. Latner, "Clinical biochemistry," in Cantarow and Trumper, pp. 147-259, W. B. Saunderss, Philadelphia, Pa, USA, 7thedition, 1975.
43. C. C. Allain, L. S. Poon, C. S. Chan, W. Richmond, and P. C. Fu, "Enzymatic determination of total serum cholesterol," Clinical Chemistry, vol. 20, no. 4, pp. 470-475, 1974.
44. D. Steinberg, "Metabolism of lipoproteins at the cellular level in relation to atherogenesis," in Lipoproteins, Atherosclerosis and Coronary Heart Disease, vol. 1, pp. 2-11, 1981.
45. P. Fossati and L. Prencipe, "Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide," Clinical Chemistry, vol. 28, no. 10, pp. 2077-2080, 1982.
46. J.-. Fruchart, I. Kora, C. Cachera, V. Clavey, P. Duthilleul, and Y. Moschetto, "Simultaneousmeasurement of plasma apolipoproteins A-I and B by electroimmunoassay," Clinical Chemistry, vol. 28, no. 1, pp. 59-62, 1982.
47. N. F. Suttle, "Copper deficiency in ruminants; recent developments," Veterinary Record, vol. 119, no. 21, pp. 519-522, 1986.
48. D. E. Paglia and W. N. Valentine, "Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase," The Journal of Laboratory and Clinical Medicine, vol. 70, no. 1, pp. 158-169, 1967.
49. H. Esterbauer, R. J. Schaur, and H. Zollner, "Chemistry and biochemistry of 4-hyroxynonenal, malonaldehyde and related aldehydes," Free Radical Biology and Medicine, vol. 11, no. 1, pp. 81-128, 1991.
50. H. Moshage, B. Kok, J. R. Huizenga, and P. L. M. Jansen, "Nitrite and nitrate determinations in plasma: a critical evaluation," Clinical Chemistry, vol. 41, no. 6, pp. 892-896, 1995.
51. A. E. Ciarlone and J. W. Smudski, "Lidocaine's influence on the accumulation and depletion rates of mouse brain amines," Journal of Dental Research, vol. 56, no. 11, pp. 1391-1394, 1977.
52. K. B. Burrows and B. K. Yamamoto, "Methamphetamine neurotoxicity: roles for glutamate, oxidative processes and metabolic stress," in Glutamate and Addiction, B. H. Herman, Ed., pp. 211-227, Humana Press, Totowa, NJ, USA, 2003.
53. J. L. Cadet, "Roles of glutamate, nitric oxide, oxidative stress, and apoptosis in the neurotoxicity of methamphetamine," in Glutamate and Addiction, B. H. Herman, Ed., pp. 201-210, Humana Press, Totowa, NJ, USA, 2003.
54. A. E. Fleckenstein, J. W. Gibb, and G. R. Hanson, "Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity," European Journal of Pharmacology, vol. 406, no. 1, pp. 1-13,2000.
55. P. Melo, L. G. Rodrigues, M. D. Pinazo-Durán, and M. A. Tavares, "Methamphetamine and lipid peroxidation in the rat retina," Birth Defects Research A, vol. 73, no. 6, pp. 455-460, 2005.
56. B. Giros, M. Jaber, S. R. Jones, R. M. Wightman, and M. G. Caron, "Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter," Nature, vol. 379, no. 6566, pp. 606-612, 1996.
57. G. Stumm, J. Schlegel, T. Schäfer et al., "Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons," The FASEB Journal, vol. 13, no. 9, pp. 1065-1072, 1999.
58. K. B. Burrows and B. K. Yamamoto, "Methamphetamine neurotoxicity: roles for glutamate, oxidative processes and metabolic stress," in Glutamate and Addiction, B. H. Herman, Ed., pp. 211-227, Humana Press Inc, New Jersey, NJ, USA, 2003.
59. P. Martin and L. S. Friedman, "Management of chronic liverdisease-Preface," in Handbook of Liver Disease, L. Friedman and E. Keeffe, Eds., pp. 1-20, Churchill Livingstone, Philadelphia, Pa, USA, 1998.
60. G. L. Plaa and W. R. Hewitt, "Detection and evaluation of chemical induced liver injury," in Principles and Methods of Toxicology, W. A. Hayes, Ed., pp. 599-614, Raven Press, New York, NY, USA, 2nd edition, 1989.
61. G. E. Gray and M. M. Meguid, "Can total parenteral nutrition reverse hypoalbuminemia in oncology patients?" Nutrition, vol. 6, no. 3, pp. 225-228, 1990.
62. J. V. Formica, "Review of the biology of quercetin and related bioflavonoids," Food and Chemical Toxicology, vol. 33, no. 12, pp. 1061-1080, 1995.
63. D. V. R. de Sotillo and M. Hadley, "Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats," The Journal of Nutritional Biochemistry, vol. 13, no. 12, pp. 717-726, 2002.
64. C. Wan, C. N. Wong, W. Pin et al., "Chlorogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by up-regulating the gene expression of PPAR-α in hypercholesterolemic rats induced with a high-cholesterol diet," Phytotherapy Research, vol. 27, no. 4, pp. 545-551, 2013.
65. H. Harnafi, M. Ramchoun, M. Tits et al., "Phenolic acidrich extract of sweet basil restores cholesterol and triglycerides metabolism in high fat diet-fed mice: a comparison with fenofibrate," Biomedicine and Preventive Nutrition, vol. 3, no. 4, pp. 393-397, 2013.
66. K. M. M. Koriem, A. Z. Abdelhamid, and H. F. Younes, "Caffeic acid protects tissue antioxidants and DNA content in methamphetamine induced tissue toxicity in Sprague Dawley rats," Toxicology Mechanisms and Methods, vol. 23, no. 2, pp. 134-143, 2013.
67. Y. Sato, S. Itagaki, T. Kurokawa et al., "In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid," International Journal of Pharmaceutics, vol. 403, no. 1-2, pp. 136-138, 2011.
68. M. J. Cejudo-Bastante, E. Durán-Guerrero, R. Natera-Marín, R. Castro-Mejías, and C. García-Barroso, "Characterisation of commercial aromatised vinegars: Phenolic compounds, volatile composition and antioxidant activity," Journal of the Science of Food and Agriculture, vol. 93, no. 6, pp. 1284-1302, 2013.
69. M. Huang, S. Lin, C. Chen, C. Pan, C. Lee, and H. Liu, "Oxidative stress status in recently abstinent methamphetamine abusers," Psychiatry and Clinical Neurosciences, vol. 67, no. 2, pp. 92-100, 2013.
70. P. Melo, V. Zanon-Moreno, C. J. Alves et al., "Oxidative stress response in the adult rat retina and plasma after repeated administration of methamphetamine," Neurochemistry International, vol. 56, no. 3, pp. 431-436, 2010.
71. A. Ajjimaporn, S. Shavali, M. Ebadi, and P. Govitrapong, "Zinc rescues dopaminergic SK-N-SH cell lines from methamphetamine-induced toxicity," Brain Research Bulletin, vol. 77, no. 6, pp. 361-366, 2008.
72. H. Solhi, A. Malekirad, A. M. Kazemifar, and F. Sharifi, "Oxidative stress and lipid peroxidation in prolonged users of methamphetamine," Drug Metabolism Letters, vol. 7, no. 2, pp. 79-82, 2014.
73. M. Teraoka, K. Nakaso, C. Kusumoto et al., "Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells," Journal of Clinical Biochemistry and Nutrition, vol. 51, no. 2, pp. 122-127, 2012.